Then, we checked FTX mRNA levels in collected clinical samples from NSCLC patients, and real‐time PCR data suggested that 74% (37/50) of NSCLC tumour samples exhibited reduced FTX expression compared to adjacent normal tissues (Figure 1B). This evidence concerns the gene FTX and non-small cell lung carcinoma.